Controlled-release cnp agonists with increased nep stability
AssigneeAscendis Pharma Growth Disorders A/S
InventorsKennett SPROGØE, Harald RAU, Ana BERNHARD, Ulrich HERSEL, Felix CLEEMANN, Thomas WEGGE
Life of this patent
Estimating the term…
Abstract
The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
Claims18
1-19. (canceled)
A method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases which can be treated with a CNP agonist, comprising the step of administering to the patient a therapeutically effective amount of a controlled-release CNP agonist or a pharmaceutical composition comprising the controlled-release CNP agonist, wherein the controlled-release CNP agonist releases one or more CNP agonist and wherein the controlled-release CNP agonist has an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist.
Dependencies are inferred from the claim text.